DSGN — Design Therapeutics Share News
0.000.00%
Last trade - 00:00- $656.48m
- $449.09m
Design Therapeutics Q2 net loss narrower than expected
Brief: Design Therapeutics Q2 Basic EPS USD -0.32
Design Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Design Therapeutics Announces Initiation Of Patient Dosing In Phase 1 Multiple Ascending Dose Trial Of Dt-818 For Myotonic Dystrophy Type-1
U.S. STOCKS ON THE MOVE-Eli Lilly, BlackRock TCP Capital, Boston Scientific
Design Therapeutics falls after early-stage data for genetic disorder treatment
Brief: Design Therapeutics Announces Four-Week IV Data From The RESTORE-FA Trial Of DT-216P2 Demonstrating Clinical Improvements And Comprehensive Biomarker Activity In Friedreich Ataxia
U.S. RESEARCH ROUNDUP-Coca-Cola Co, Mondelez, Zeta Global Holdings
Design Therapeutics Q1 net loss narrows, beats analyst estimates
Brief: Design Therapeutics Q1 Basic EPS USD -0.29
U.S. RESEARCH ROUNDUP- Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics
Design Therapeutics reports lower-than-expected Q4 net loss
Brief: Design Therapeutics Q4 Basic EPS USD -0.27
U.S. RESEARCH ROUNDUP- Blackline, Carmax, Expedia
U.S. RESEARCH ROUNDUP-Acadia Pharmaceuticals, Applovin Corp, Centuri Holdings
Design Therapeutics' reports lower-than-expected Q3 loss
Brief: Design Therapeutics Q3 Basic EPS USD -0.3
Design Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Design Therapeutics Q2 Basic EPS USD -0.34